- Prevalence of asthma-COPD overlap syndrome (ACOS) was high in newly-diagnosed patients with COPD.
- Different diagnostic criteria produced wide variation in proportion of patients with ACOS.
Why this matters
- First study to apply different ACOS definitions in the same cohort.
- ACOS prevalence was 6.8% overall and 37.8% in newly-diagnosed patients with COPD.
- Compared to COPD-only patients, patients with ACOS were younger, had more dyspnea, lower FEV1 and FEV1:FVC, but no difference in pack-years.
- Patients with ACOS and wheeze (ACOS-W) had more dyspnea than those without wheeze (P<.0001).
- Patients with ACOS-W were younger (P=.02), had higher BMI (P<.01), lower post-bronchodilator (BD) FEV1:FVC (P=.02), and lower post-BD FEV1% predicted (P<.0001), but no significant difference in pack-years and post-BD FEV1 increase.
- Patients with ACOS-BD reversibility (BDR) had lower FEV1:FVC (P=.03), but no significant difference in age, BMI, pack-years or FEV1% predicted.
- Patients with ACOS-W+BDR had more dyspnea than patients with ACOS-W- and ACOS-BDR-only (P<.01 for both), but no differences in age, pack-years, FEV1% predicted or FEV1:FVC.
- Primary care screening of 3875 patients aged ≥35 y, with tobacco exposure, ≥1 respiratory symptom, and no previous COPD diagnosis.
- Funding: Boehringer-Ingelheim and Pfizer.
- No gold-standard diagnostic criteria for ACOS.
- Danish-only population.